Emergent BioSolutions Inc.’s (EBS) anthrax vaccine candidate AV7909 awaits the FDA decision in April.AV7909, a next-generation vaccine, is proposed for post-exposure prophylaxis of anthrax following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs.The company already has an approved anthrax vaccine named BioThrax, indicated for active immunization for the prevention of disease caused by Bacillus anthracis, in persons 18 – 65 years of age at high risk of exposure.AV7909 is a combination of BioThrax and vaccine adjuvant CPG 7909.EBS closed Thursday’s trading at $10.18.